|
|
|
Insider
Information: |
Shabet Rose Sharon |
Relationship: |
|
City: |
Greenwich |
State: |
CT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
415,583,308 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$3,592,310,899 |
|
|
Total
Shares |
415,583,308 |
|
|
Total
Value |
$3,592,310,899 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
8
|
Stock
price went up :
|
1
|
2
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
Percentage
Gain/Loss : |
183.9%
|
-174.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Tekmira Pharmaceuticals Corp |
TKMR |
10% Owner |
|
0 |
2017-07-01 |
16,013,540 |
Premium* |
|
Sio Gene Therapies Inc |
SIOX |
10% Owner |
|
0 |
2019-03-18 |
105,952,381 |
Premium* |
|
Myovant Sciences Ltd. |
MYOV |
10% Owner |
|
0 |
2019-06-04 |
40,765,599 |
Premium* |
|
Urovant Sciences Ltd. |
UROV |
10% Owner |
2018-10-01 |
0 |
2019-06-19 |
22,860,013 |
Premium* |
|
Adaptive Biotechnologies Corp |
ADPT |
10% Owner |
|
0 |
2020-12-14 |
29,993,708 |
Premium* |
|
Bridgebio Pharma, Inc. |
BBIO |
|
2019-06-27 |
0 |
2023-07-18 |
25,120,991 |
Premium* |
|
Zentalis Pharmaceuticals, Llc |
ZNTL |
10% Owner |
|
0 |
2020-12-01 |
3,943,284 |
Premium* |
|
Inhibrx, Inc. |
INBX |
|
2020-08-24 |
0 |
2023-08-28 |
7,150,826 |
Premium* |
|
4d Molecular Therapeutics Inc. |
FDMT |
|
2020-12-15 |
0 |
2024-01-04 |
4,247,914 |
Premium* |
|
Rallybio Corp |
RLYB |
10% Owner |
2021-07-29 |
0 |
2021-07-29 |
4,194,777 |
Premium* |
|
Figs, Inc. |
FIGS |
10% Owner |
2021-09-02 |
0 |
2021-09-03 |
14,742,689 |
Premium* |
|
Procept Biorobotics Corp |
PRCT |
|
|
0 |
2021-09-14 |
308,142 |
Premium* |
|
Ginkgo Bioworks Holdings, Inc |
DNA |
|
|
0 |
2022-03-02 |
51,055,144 |
Premium* |
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2022-01-11 |
0 |
2022-01-11 |
2,300,000 |
Premium* |
|
Frazier Lifesciences Acquisition... |
FLAC |
|
2022-11-02 |
0 |
2022-11-02 |
1,211,582 |
Premium* |
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
0 |
2024-02-26 |
0 |
Premium* |
|
Api Group Corp |
APG |
|
2024-01-02 |
0 |
2024-03-05 |
27,071,548 |
Premium* |
|
Fluidigm Corp |
FLDM |
|
|
0 |
2024-03-18 |
58,651,170 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
74 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-05-31 |
4 |
AB |
$7.70 |
$39,042 |
I/I |
5,071 |
22,771,914 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-03 |
4 |
AB |
$7.71 |
$41,815 |
I/I |
5,424 |
22,777,338 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-04 |
4 |
AB |
$7.59 |
$56,911 |
I/I |
7,500 |
22,784,838 |
0 |
- |
|
MYOV |
Myovant Sciences Ltd. |
10% Owner |
|
2019-06-04 |
4 |
B |
$8.25 |
$19,999,997 |
I/I |
2,424,242 |
40,765,599 |
1.5 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-05 |
4 |
AB |
$8.02 |
$52,418 |
I/I |
6,540 |
22,791,378 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-06 |
4 |
AB |
$8.00 |
$56,621 |
I/I |
7,082 |
22,798,460 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-07 |
4 |
AB |
$7.97 |
$52,959 |
I/I |
6,649 |
22,805,109 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-10 |
4 |
AB |
$8.35 |
$62,594 |
I/I |
7,500 |
22,812,609 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-11 |
4 |
AB |
$8.58 |
$61,694 |
I/I |
7,189 |
22,819,798 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-12 |
4 |
AB |
$8.30 |
$62,244 |
I/I |
7,500 |
22,827,298 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-13 |
4 |
AB |
$7.95 |
$58,543 |
I/I |
7,367 |
22,834,665 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-14 |
4 |
AB |
$7.91 |
$56,514 |
I/I |
7,144 |
22,841,809 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-17 |
4 |
AB |
$8.53 |
$55,825 |
I/I |
6,541 |
22,848,350 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-18 |
4 |
AB |
$8.21 |
$55,061 |
I/I |
6,706 |
22,855,056 |
0 |
- |
|
UROV |
Urovant Sciences Ltd. |
10% Owner |
|
2019-06-19 |
4 |
AB |
$8.17 |
$40,495 |
I/I |
4,957 |
22,860,013 |
0 |
- |
|
BBIO |
Bridgebio Pharma, Inc. |
10% Owner |
|
2019-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
21,915,091 |
21,915,091 |
0 |
- |
|
BBIO |
Bridgebio Pharma, Inc. |
10% Owner |
|
2019-06-27 |
4 |
B |
$17.00 |
$80,000,300 |
I/I |
4,705,900 |
26,620,991 |
1.5 |
- |
|
ADPT |
Adaptive Biotechnologies ... |
10% Owner |
|
2019-07-01 |
4 |
B |
$20.00 |
$5,000,000 |
I/I |
250,000 |
1,675,000 |
1.5 |
- |
|
ADPT |
Adaptive Biotechnologies ... |
10% Owner |
|
2019-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
36,731,607 |
38,406,607 |
0 |
- |
|
ADPT |
Adaptive Biotechnologies ... |
10% Owner |
|
2020-01-28 |
4 |
S |
$24.98 |
$122,706,039 |
I/I |
(4,912,899) |
33,493,708 |
0 |
% |
|
ZNTL |
Zentalis Pharmaceuticals,... |
10% Owner |
|
2020-04-07 |
4 |
B |
$18.00 |
$13,050,000 |
I/I |
725,000 |
4,443,284 |
1.5 |
- |
|
INBX |
Inhibrx, Inc. |
10% Owner |
|
2020-08-24 |
4 |
B |
$19.43 |
$897,001 |
I/I |
46,161 |
1,161,784 |
1.5 |
- |
|
INBX |
Inhibrx, Inc. |
10% Owner |
|
2020-08-25 |
4 |
B |
$19.23 |
$1,651,687 |
I/I |
85,304 |
1,247,088 |
1.5 |
- |
|
INBX |
Inhibrx, Inc. |
10% Owner |
|
2020-08-26 |
4 |
B |
$18.84 |
$3,409,866 |
I/I |
180,219 |
1,427,307 |
1.5 |
- |
|
ADPT |
Adaptive Biotechnologies ... |
10% Owner |
|
2020-11-11 |
4 |
S |
$49.52 |
$123,787,500 |
I/I |
(2,500,000) |
30,993,708 |
0 |
% |
|
74 Records found
|
|
Page 2 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|